Bivalirudin is a thrombin –inhibiting oligopeptide that was developed through rational drug as a hirudin analogue. It is a thrombin inhibitor consisting of 20 –amino acid structure combining a carboxy-terminal region that recognizes thrombin’s fibrin (ogen)- binding sate. It works by blocking of the formation of blood clots. Likewise, desmopressin is an antidiuretic harmone. It works by causing the kidneys to produce less urine. Bivalirudin is used as an anticoagulant in the patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA) and in patients undergoing percutaneous coronary intervention (PCI). Moreover, Bivalirudin is used in conjuction with other medicines. Further, desmopressin is used to manage temporarily increased thirst and urination caused by head injury.
Market Size and Forecast
Global Bivalirudin and Desmopressin Market is expected to increase significantly over the forecast period 2017-2024. The bivalirudin is facing increased demand due to its application in the treatment of coronary artery disease and cancer. Likewise, the demand for desmopressin is increasing due to its use in bedtime wetting and nocturia.
For Sample Pages please go through link below:
By Region – North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis, Latin America (Brazil, Mexico, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis, Western and Eastern Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, Rest of Western Europe) Market size, Y-O-Y growth & Opportunity Analysis, Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia) Market size, Y-O-Y growth & Opportunity Analysis.
Growth Drivers and Challenges
The market growth is driven by the rise in the number of the cases of cardiovascular diseases. According to the American Heart Association, the number of the adults living with the heart failure has increased from 5.7 million (2009-12) to about 6.5 million (2011-2014). Further, the cardiovascular diseases are on rise thereby leading to the increased number of deaths across the world. The cardiovascular diseases include coronary artery disease, high blood pressure and stroke. The patients with ST-elevation myocardial infarction (STEMI) is often achieved via primary percutaneous coronary intervention (PCI), thus reducing major adverse cardiovascular diseases.
Request For TOC Here:
Adjunctive antithrombotic and antiplatelet therapies are used during PCI to reduce MACE rates. The most commonly used agents include low unfractioned heparin. These agents reduce the rates of peri-procedural ischemic and thrombotic events, but these agents produce complications in the form of increased bleeding, but bivalirudin has emerged as a safe alternative to heparin and helps in reducing the risk of coronary artery disease. Moreover, bivalirudin has advantages over the heparin including reduced rates of mortality, cardiovascular mortality and major bleeding events. Therefore, this has led to the adoption of bivalirudin as a drug for the treatment of coronary artery disease, thus leading to the expansion of the bivalirudin market. The increase in the number of cancer patients is another reason that is driving the growth of bivalirudin market.
According to the World Health Organization (WHO), approximately 14 million cases came into the light in 2012. Moreover, the cancer is second leading cause of the death globally, and was responsible for 8.8 million deaths in 2015. The expansion of the desmopressin market is driven by the increasing number of nocturia cases among elderly men and women. Nocturia is a lower urinary tract symptom which involves the need for passing urine at night, resulting in the disturbance of sleep. As a result, it frequently impacts upon the quality of life (QoL) and wellbeing of individuals.
The prevalence increases with the age and has reported to be as high as 77% and 94% in elderly women and men respectively, thus leading to the expansion of the desmopressin market. Desmopressin works as an effective treatment for patients with nocturia. The antidiuretic effect of desmopressin decreases the number of the night voids and prolongation of the sleep period as compared to placebo. However, the market growth of Bivalirudin is hindered by various reasons including the cost and the reluctance to change from existing anti-thrombotic agents used.
Key Players – Pfizer, Inc. (US), Company Overview, Key Product Offerings, Business Strategy, SWOT Analysis, Financials, Bayer Healthcare AG (Germany), GlaxoSmithKline PLC. (UK), Abott India Limited (India), Mitsubishi Tanabe Pharma Corporation (Japan), Sun Pharmaceuticals Industries Limited, Ferring Pharmaceuticals, Eisai Inc., Boehringer Ingelheim
To know more about this research, kindly visit:
For Table of Content & Free Sample Report Contact:
Name:- Ajay Daniel
1820 Avenue M, Suite# 1113,
Brooklyn, New York 11230
U.S. +1 646 586 9123
U.K. +44 203 608 5919